ZOLYMBUS bimatoprost .1 mg/g Gel — NDC 82584-010-10 (Billing 82584-0010-10)
This is a package of ZOLYMBUS bimatoprost .1 mg/g Gel from Thea Pharma Inc., marketed since Feb 2026 and currently FDA-listed. It is the main listing for this product, which comes in 3 package sizes.
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 088224
- GCN: 58324
- GPI-14 (Medi-Span): 86330015004010
- HICL (First Databank): 040034
- AHFS class code: 52:40.28.00
- RxCUI (RxNorm): 2725168
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Prostaglandin Analog class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
- It depends on the product you have. Lumigan, Zolymbus and Durysta lower high eye pressure in open-angle glaucoma or ocular hypertension. Latisse and generic bimatoprost 0.03% are f...
- Lumigan and Zolymbus are one drop in the eye once daily in the evening. Latisse and generic bimatoprost 0.03% go on the upper eyelid margin once nightly with a fresh sterile applic...
- Red, itchy or dry eyes are common, and you may notice lash growth or darker skin around the eye. Most of these are mild. Call me or your doctor if you have eye pain, vision changes...
- Yes. It can make the iris more brown, and this is likely to be permanent. It may take months or years to notice. Your doctor can talk with you about this.
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Bimatoprost — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 3, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 82584-0010-10 You're viewing this Main listing | 1 POUCH in 1 CARTON / 10 VIAL, SINGLE-DOSE in 1 POUCH / .3 g in 1 VIAL, SINGLE-DOSE Sample | 2026-02-26 | — | Active |
| 82584-0010-30 82584-010-30 | 3 POUCH in 1 CARTON / 10 VIAL, SINGLE-DOSE in 1 POUCH / .3 g in 1 VIAL, SINGLE-DOSE | 2026-02-26 | — | Active |
| 82584-0010-35 82584-010-35 | 3 POUCH in 1 CARTON / 10 VIAL, SINGLE-DOSE in 1 POUCH / .3 g in 1 VIAL, SINGLE-DOSE Sample | 2026-02-26 | — | Active |
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of ZOLYMBUS bimatoprost .1 mg/g Gel?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Zolymbus .1 mg/gthis 82584-0010-10 | Thea | 1 pouch | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Sep 3, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route. Patent/protection dates below may affect future generic timing.
Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.
🛈 What do these terms mean?
- Patent
- Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
- Substance patent
- Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
- Formulation (product) patent
- Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
- Method-of-use patent
- A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
- Skinny label
- A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
- Exclusivity
- FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
- Paragraph IV
- A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
- RLD / RS
- Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
- TE / AB rating
- FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
- LOE (loss of exclusivity)
- The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.
Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.
| Patent | Type | Use code | Expires |
|---|---|---|---|
| US 10314780 ↗ | Method of use | U-1295 | Jun 8, 2036 |
| Code | What it grants | Expires |
|---|---|---|
| NDF | New Dosage Form | Sep 9, 2028 |
Is there a generic version of ZOLYMBUS 0.01% EYE DROPS?
The FDA approved a generic — why can’t I get it at my pharmacy yet?
Why do different websites show different generic release dates?
What does “FDA listed” mean?
What does a patent or protection date mean here?
What does “current Orange Book estimate” mean?
Can a generic come out before the last patent expires?
Can a generic come out after the listed dates?
What is the difference between patents and exclusivity?
Why are there multiple patent dates?
Where does this data come from?
- FDA Orange Book · refreshed Sep 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII HHT01ZNK31
Carbomer Homopolymer Type B is a synthetic polymer made from acrylic acid. It absorbs water and forms a gel, so it's used in medicines as a thickener, suspending agent, and to help create a smooth texture in creams, gels, and lotions.
-
UNII 4R4HFI6D95
Polyethylene glycol 4000 is a synthetic polymer derived from petroleum. It serves as a binder, filler, and lubricant in solid dosage forms, and helps control how quickly the medicine dissolves.
-
UNII 4550K0SC9B
Sodium acetate is a salt derived from acetic acid. It acts as a buffer to help maintain the medicine's pH stability and may serve as a preservative or solubilizer in liquid formulations.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
-
UNII 506T60A25R
Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
6 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 1, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE ZOLYMBUS™ is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ZOLYMBUS™ is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION The recommended dosage is one drop in the affected eye(s) once daily in the evening. ZOLYMBUS should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the IOP lowering effect. Reduction of the IOP starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours.
ZOLYMBUS may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. If one dose is missed, treatment should continue with the next dose as normal.
The gel from one single-dose container is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be maintained after the single-dose container is opened, discard the open container and the remaining contents immediately after administration. One drop in the affected eye(s) once daily in the evening.
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Ophthalmic gel: 0.01% bimatoprost as a colorless, opalescent gel in a single-dose container. Ophthalmic gel: 0.01% bimatoprost in a single-dose container.
⛔ Contraindications ▾
4 CONTRAINDICATIONS ZOLYMBUS is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients [see Adverse Reactions (6.2) ] . Hypersensitivity.
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Pigmentation : Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. ( 5.1 ) Eyelash Changes : Gradual change to eyelashes including increased length, thickness and number of lashes. Usually, reversible. ( 5.2 )
5.1Pigmentation Bimatoprost has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as bimatoprost is administered.
The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of bimatoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation.
The long term effects of increased pigmentation are not known. Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish.
Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with ZOLYMBUS can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.
5.2Eyelash Changes ZOLYMBUS may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.
5.3Intraocular Inflammation Prostaglandin analogs, including bimatoprost, have been reported to cause intraocular inflammation. ZOLYMBUS should be used with caution in patients with active intraocular inflammation (e.g., iritis/uveitis) because inflammation may be exacerbated.
5.4Macular Edema Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic products. ZOLYMBUS should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
5.5Contact Lens Use Contact lenses should be removed prior to the administration of ZOLYMBUS and may be reinserted 15 minutes after administration.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following adverse reactions are described elsewhere in the labeling: Pigmentation including blepharal pigmentation and iris hyperpigmentation [see Warnings and Precautions (5.1) ] Eyelash Changes [see Warnings and Precautions (5.2) ] Intraocular Inflammation [see Warnings and Precautions (5.3) ] Macular Edema [see Warnings and Precautions (5.4) ] Hypersensitivity [see Contraindications (4) ] Most common adverse reactions (≥10%) are conjunctival hyperemia (14%) and eye irritation (11%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Thea Pharma Inc. at 1-833-838-4028 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In the two clinical trials conducted with ZOLYMBUS (bimatoprost ophthalmic gel) 0.01% comparing it to preserved bimatoprost ophthalmic solution 0.01%, the most frequently reported ocular adverse reactions were conjunctival hyperemia (14%), eye irritation (11%), eye pruritus (9%) and foreign body sensation in eyes (8%).
Other adverse drug reactions (reported in 1% to 6% of patients) with ZOLYMBUS in the studies included dry eye, abnormal sensation in eye, lacrimation increased, eye pain, and vision blurred.
6.2Postmarketing Experience The following adverse reactions have been identified during post-approval use of topical bimatoprost products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to bimatoprost, or a combination of these factors include: asthma-like symptoms, dizziness, dry eye, dyspnea, eye discharge, eye edema, foreign body sensation, headache, hypersensitivity including signs and symptoms of eye allergy and allergic dermatitis, hypertension, lacrimation increased, periorbital and lid changes associated with periorbital fat atrophy leading to skin tightness, deepening of the eyelid sulcus, eyelid ptosis, enophthalmos, and eyelid retraction; and photophobia.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use. ( 8.4 )
8.1Pregnancy Risk Summary There are no adequate and well-controlled studies of ZOLYMBUS (bimatoprost ophthalmic gel) 0.01% administration in pregnant women. There is no increase in the risk of major birth defects or miscarriages based on bimatoprost post-marketing experience. In embryofetal developmental studies, administration of bimatoprost to pregnant mice and rats during organogenesis, resulted in abortion and early delivery at oral doses at least 33 times (mice) or 94 times (rats) the human exposure to bimatoprost solution 0.03% dosed bilaterally once daily (based on blood area under the curve [AUC] levels).
These adverse effects were not observed at 2.6 times (mice) and 47 times (rats) the human exposure to bimatoprost 0.03% dosed bilaterally once daily (based on blood AUC levels). In pre/postnatal development studies, administration of bimatoprost to pregnant rats from organogenesis to the end of lactation resulted in reduced gestation length and fetal body weight, and increased fetal and pup mortality at oral doses at least 41 times the human systemic exposure to bimatoprost solution 0.03% dosed bilaterally once daily (based on blood AUC levels).
No adverse effects were observed in rat offspring at exposures estimated at 14 times the human exposure to bimatoprost solution 0.03% dosed bilaterally once daily (based on blood AUC levels). Because animal reproductive studies are not always predictive of human response ZOLYMBUS should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown.
However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies. Data Animal Data In an embryofetal development rat study, abortion was observed in pregnant rats administered bimatoprost orally during organogenesis at 0.6 mg/kg/day (94 times the human systemic exposure to bimatoprost solution 0.03% dosed bilaterally once daily, based on AUC). The No Observed Adverse Effect Level (NOAEL) for abortion was 0.3 mg/kg/day (estimated at 47 times the human systemic exposure to bimatoprost solution 0.03% dosed bilaterally once daily, based on AUC).
No abnormalities were observed in rat fetuses at doses up to 0.6 mg/kg/day. In an embryofetal development mouse study, abortion and early delivery were observed in pregnant mice administered bimatoprost orally during organogenesis at doses greater than or equal to 0.3 mg/kg/day (33 times the human systemic exposure to bimatoprost solution 0.03% dosed bilaterally once daily, based on AUC). The NOAEL for abortion and early delivery was 0.1 mg/kg/day (2.6 times the human systemic exposure to bimatoprost solution 0.03% dosed bilaterally once daily, based on AUC).
No abnormalities were observed in mouse fetuses at doses up to 0.6 mg/kg/day (72 times the human systemic exposure to bimatoprost solution 0.03% dosed bilaterally once daily based on AUC). In a pre/postnatal development study, treatment of pregnant rats with bimatoprost orally from gestation day 7 to lactation day 20 resulted in reduced gestation length, increased late resorptions, fetal deaths, and postnatal pup mortality, and reduced pup body weight at doses greater than or equal to 0.3 mg/kg/day. These effects were observed at exposures at least 41 times the human systemic exposure to bimatoprost solution 0.03% dosed bilaterally once daily, based on AUC.
The NOAEL for postnatal development and mating performance of the offspring was 0.1 mg/kg/day (estimated at 14 times the human systemic exposure to bimatoprost solution 0.03% dosed bilaterally once daily, based on AUC).
8.2Lactation Risk… [Excerpted — this section continues on DailyMed.]
🆘 Overdosage ▾
10 OVERDOSAGE No information is available on overdosage in humans. If overdose with ZOLYMBUS occurs, treatment should be symptomatic. In oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m 2 is at least 90 times higher than the accidental dose of the entire content of a pack of ZOLYMBUS (30 x 0.3 g single-dose containers; 9 g) for a 10 kg child.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.
Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
12.3Pharmacokinetics Absorption After one drop of bimatoprost ophthalmic gel 0.01% was administered once daily to both eyes of 20 healthy participants for two weeks, blood concentrations peaked within 10 minutes after dosing and were below the lower limit of detection (5 pg/mL) in most subjects within 30 minutes after dosing. Mean C max values were similar on days 1 and 14 at 0.021 ng/mL and 0.028 ng/mL, respectively, indicating that a steady state was reached. There was no significant systemic drug accumulation over time.
Distribution Bimatoprost is moderately distributed into body tissues with a steady-state volume of distribution of
0.67L/kg. In human blood, bimatoprost resides mainly in the plasma. Approximately 12% of bimatoprost remains unbound in human plasma.
Elimination Metabolism Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing. Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form a diverse variety of metabolites. Excretion Following an intravenous dose of radiolabeled bimatoprost (3.12 mcg/kg) to six healthy subjects, the maximum blood concentration of unchanged drug was 12.2 ng/mL and decreased rapidly with an elimination half-life of approximately 45 minutes.
The total blood clearance of bimatoprost was
1.5L/hr/kg. Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING ZOLYMBUS (bimatoprost ophthalmic gel) 0.01% is supplied as a colorless, opalescent gel in blow-fill-seal single-dose container packaged in foil pouches. 10 single-dose containers per pouch. NDC 82584-010-30; Carton of 30 single-dose containers Storage: Store at 20°C to 30°C (68°F to 86°F).
Protect from light. Store in the original pouch. After the pouch is opened, the single-dose containers may be stored in the opened foil pouch for up to 14 days at 20°C to 30°C (68°F to 86°F).
Patient should be advised to write down the date the foil pouch is opened in the space provided on the pouch. Discard any unused containers 14 days after first opening the pouch. Single-dose container.
Discard unused portion.
📋 Description ▾
11 DESCRIPTION ZOLYMBUS contains bimatoprost, a synthetic prostamide analog with ocular hypotensive activity, for topical ophthalmic use. The chemical name is 5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2- [(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl, (5Z)-, with the molecular weight 415.58 and molecular formula is C 25 H 37 NO 4 . Its chemical structure is: Bimatoprost is a crystalline powder, which is very soluble in ethyl alcohol and methyl alcohol and slightly soluble in water.
ZOLYMBUS is a sterile, colorless, opalescent ophthalmic gel with an osmolality of approximately 300 mOsmol/kg. Each container contains 0.03 mg of bimatoprost and the following inactive ingredients: carbomer, polyethylene glycol, sodium acetate trihydrate, sorbitol, sodium hydroxide and water for injection with a pH range from 6.9 to 7.9. ZOLYMBUS does not contain a preservative.
Chemical structure
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Potential for Pigmentation Advise patients about the potential for increased brown pigmentation of the iris, which may be permanent. Also inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of ZOLYMBUS (bimatoprost ophthalmic gel).
Potential for Eyelash Changes Inform patients of the possibility of eyelash and vellus hair changes in the treated eye during treatment with ZOLYMBUS. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment.
Handling the Container Advise patients that ZOLYMBUS is a sterile gel that does not contain a preservative. The drops are supplied in a single-dose container. The gel from one single-dose container is to be used immediately after opening for administration to one or both eyes.
Since sterility cannot be maintained after the single-dose container is opened, discard the open container and the remaining contents immediately after administration. Open a new single-dose container every time you use ZOLYMBUS. When to Seek Physician Advice Advise patients that if they develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician’s advice concerning the continued use of ZOLYMBUS.
Contact Lens Use Advise patients that contact lenses should be removed prior to administration of ZOLYMBUS. Lenses may be reinserted 15 minutes following administration of ZOLYMBUS. Use with Other Ophthalmic Drugs Advise patients that if more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
If a Dose is Missed Advise patients that if one dose is missed, treatment should continue with the next dose as normal. Manufactured for: Thea Pharma Inc. Waltham, MA 02451.
U.S. Patent N°. 10,314,780. ©2025, Laboratoires Théa.
All rights reserved. ZOLYMBUS™ is a trademark of Laboratoires Théa.
🔬 Clinical Studies ▾
14 CLINICAL STUDIES In a 12-week clinical trial of patients with open-angle glaucoma or ocular hypertension with a mean baseline IOP of 23 to 24 mmHg, the IOP-lowering effect of ZOLYMBUS once daily (in the evening) was non-inferior to preserved bimatoprost ophthalmic solution 0.01%.
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Bimatoprost was not carcinogenic in either mice or rats when administered by oral gavage for 104 weeks at doses up to 2 mg/kg/day and 1 mg/kg/day, respectively (192 and 291 times the estimated human systemic exposure to bimatoprost solution 0.03% dosed bilaterally once daily, respectively, based on blood AUC levels). Mutagenesis Bimatoprost was not mutagenic or clastogenic in the Ames test, in the mouse lymphoma test, or in the in vivo mouse micronucleus tests.
Impairment of Fertility Bimatoprost did not impair fertility in male or female rats up to doses of 0.6 mg/kg/day (at least 103 times the recommended human exposure to bimatoprost solution 0.03% dosed bilaterally once daily based on blood AUC levels).
📄 Patient Package Insert ▾
PATIENT INFORMATION ZOLYMBUS TM (zoh LIM bus) (bimatoprost ophthalmic gel 0.01%) for topical ophthalmic use This Patient Information has been approved by the U.S. Food and Drug Administration. Approved: 09/2025 What is ZOLYMBUS?
ZOLYMBUS is a prescription eye gel used to lower the pressure in the eye (intraocular pressure) in people with open-angle glaucoma or ocular hypertension when their eye pressure is too high. ZOLYMBUS belongs to a group of medicines called prostaglandin analogs. ZOLYMBUS is not recommended in children younger than 16 years of age because of the potential for eye and eyelid color changes.
Do not use ZOLYMBUS if you are allergic to bimatoprost or any of the ingredients in ZOLYMBUS. See the end of this Patient Information leaflet for a complete list of ingredients in ZOLYMBUS. Before using ZOLYMBUS, tell your healthcare provider about all your medical conditions, including if you: have or have had eye problems including any surgery on your eye or eyes are using any other eye medicines are pregnant or plan to become pregnant.
It is not known if ZOLYMBUS will harm your unborn baby. If you become pregnant while using ZOLYMBUS talk to your healthcare provider right away. are breastfeeding or plan to breastfeed. It is not known if ZOLYMBUS passes into your breast milk.
Talk to your healthcare provider about the best way to feed your baby if you use ZOLYMBUS. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take.
Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I use ZOLYMBUS? Read the Instructions for Use at the end of this Patient Information leaflet for additional instructions about the right way to use ZOLYMBUS.
Use 1 drop of ZOLYMBUS in your affected eye or eyes each evening. Talk to your healthcare provider or pharmacist if you are not sure how to use ZOLYMBUS. Your ZOLYMBUS may not work as well if you use it more than 1 time each evening.
If you miss a dose of ZOLYMBUS, skip the missed dose and use the next dose at your regular time. If you use other medicines in your eye, wait at least 5 minutes between using ZOLYMBUS and your other eye medicines. Contact lenses should be taken out before using ZOLYMBUS and you should wait at least 15 minutes after giving the dose of ZOLYMBUS before putting the contact lenses back into your eyes.
Use your ZOLYMBUS right away after opening for use in 1 or both eyes. Each ZOLYMBUS single-dose container is sterile and is to be used 1 time then thrown away. Do not save any ZOLYMBUS that may be left over after you use your medicine.
Using ZOLYMBUS that is not sterile may cause other eye problems. What are the possible side effects of ZOLYMBUS? ZOLYMBUS may cause serious side effects including: changes in the color of your eye (iris).
Your iris may become more brown in color while using ZOLYMBUS. This color change may not go away when you stop using ZOLYMBUS. If ZOLYMBUS is used in 1 eye only, the color of that eye may always be a different color from the color of your other eye. darkening of the color of the skin around your eye (eyelid).
These skin changes usually go away when you stop using ZOLYMBUS. increasing the length, thickness, color, and number of your eyelashes. These eyelash changes usually go away when you stop using ZOLYMBUS. hair growth on skin around the treated eye. This hair growth usually goes away when you stop using ZOLYMBUS. inner eye swelling (inflammation).
Swelling or thickening may occur in the center of your eye (macular edema) and swelling in the middle layer of your eye (uvea, intraocular inflammation). Tell your healthcare provider if you experience eye inflammation or have a known risk of macular edema. The most common side effects of ZOLYMBUS include: redness of and around the eye (conjunctival hyperemia) eye irritation itchy eyes (eye pruritus) dry eye foreign b… [Excerpted — this section continues on DailyMed.]
📖 Instructions for Use ▾
Instructions for Use ZOLYMBUS™ (zoh LIM bus) (bimatoprost ophthalmic gel) 0.01% for topical ophthalmic use Read this Instructions for Use before using your ZOLYMBUS™ and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.
Important Information You Need to Know Before Using ZOLYMBUS: ZOLYMBUS is for use in the eye. Do not swallow ZOLYMBUS. ZOLYMBUS single-dose containers are packaged in a foil pouch.
Do not use the ZOLYMBUS single-dose containers if the foil pouch is already opened when you receive it. Write down the date you open the foil pouch in the space provided on the pouch. Use 1 drop of ZOLYMBUS in your affected eye or eyes each evening.
If you use other eye medicines dropped into the eye (topically applied ophthalmic medicines), use the medicines at least 5 minutes before or 5 minutes after the use of ZOLYMBUS. Do not open the ZOLYMBUS single-dose container until you are ready to use the eye drops. Please follow these instructions to use ZOLYMBUS: Step 1.
Wash your hands and sit or stand comfortably. Step 2. Open the foil pouch containing a strip of 10 single-dose containers.
Write down the date of first opening on the foil pouch. Step 3. Take the strip of single-dose containers from the foil pouch.
Break off 1 single-dose container from the strip. Place the remaining strip of unopened single-dose containers back in the foil pouch and fold the edge to close the pouch. Step 4.
Hold the single-dose container upright. Make sure that your ZOLYMBUS medicine is in the bottom part of the single-dose container. Twist open the top of the single-dose container as shown.
Do not touch the tip after opening the container. Step 5. Tilt your head backwards.
If you are unable to tilt your head, lie down. Use your finger to gently pull down the lower eyelid of your affected eye. Step 6.
Place the tip of the single-dose container close to, but not touching your eye. Step 7. Squeeze the single-dose container gently so that only 1 drop goes into your eye, then release the lower eyelid.
If the drop misses your eye completely, try again. If your healthcare provider has told you to use ZOLYMBUS drops in both eyes, repeat Step 5 to Step 7 for your other eye. Each single-dose container contains enough drops for both eyes.
Throw away the single-dose container after use. Do not keep it to use it again even if there is product left in the container. To lessen the chance of infection, a new single-dose container must be opened each time you are ready to use ZOLYMBUS.
Place the folded foil pouch back in the carton. The unopened single-dose containers must be used within 14 days after opening the foil pouch. Protect from light.
Manufactured for: Thea Pharma Inc. Waltham, MA 02451. U.S.
Patent N°. 10,314,780. ©2025, Laboratoires Théa. All rights reserved.
ZOLYMBUS™ is a trademark of Laboratoires Théa. This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.
Approved: 09/2025 IFU step 3 IFU step 4 IFU step 5-6-7 Logo
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL -ophthalmic gel 0.01%; Carton of 30 single-dose containers NDC 82584-010-30 ZOLYMBUS™ (bimatoprost ophthalmic gel) 0.01% Contains: Active: bimatoprost 0.1 mg/g. Inactive ingredients: carbomer, sodium acetate trihydrate, polyethylene glycol, sodium hydroxide (for pH adjustment), sorbitol and water for injection. Recommended Dosage: one drop in the affected eye(s) once daily in the evening.
Single-dose container. Discard unused portion. Storage: Store at 20°C to 30°C (68°F to 86°F).
See Prescribing Information. 30 single-dose containers: 3 pouches x 10 single-dose containers (0.3 g each). Store in the original pouch.
After the pouch is opened, the single-dose containers may be stored in the opened foil pouch for up to 14 days. Discard any unused containers 14 days after first opening the pouch. Manufactured for Thea Pharma Inc.
Waltham, MA 02451 U.S. Patent N°. 10,314,780. ©2024, Laboratoires Théa.
All rights reserved. ZOLYMBUS™ is a trademark of Laboratoires Théa. Théa Logo Carton
PRINCIPAL DISPLAY PANEL - ophthalmic gel 0.01%; Pouch of 10 single-dose containers NDC 82584-010-81 Recommended Dosage: one drop in the affected eye(s) once daily in the evening. Single-dose container. Discard unused portion.
See carton for inactive ingredients. Storage: Store at 20°C to 30°C (68°F to 86°F). Protect from light.
Store in the original pouch. After the pouch is opened, the single-use containers may be stored in the opened foil pouch for up to 14 days. Discard any unused containers 14 days after first opening the pouch.
Write down the date you open the pouch. __ / __ / __ ZOLYMBUS™ (bimatoprost ophthalmic gel) 0.01% For Topical Ophthalmic Use 10 single-dose containers (0.3 g each) Rx only Sterile - Contains no preservatives Manufactured for Thea Pharma Inc. Waltham, MA 02451 Théa Logo Lot: EXP: Pouch
Medicare Part D spend CMS · PART D · 2026 (Q1)
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |